Bessemer Group’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Bessemer Group’s Portfolio SPPI Stock Details SPPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-87	Closed	-$1K	–	1792
2019 Q3	$1K	Buy	+87	New	+$704	﹤0.01%	1702
2013 Q3	–	Sell	-112,690	Closed	-$841K	–	1402
2013 Q2	$841K	Buy	+112,690	New	+$864K	0.01%	411

Other funds holding SPPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bessemer Group's SPPI Position: Q4 2019 in Review

Bessemer Group sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q4 2019, closing a stake of 87 shares — an estimated $1K sold.

Bessemer Group first reported a position in SPPI in Q2 2013 and held it in 2 quarters. The position peaked at $841K in Q2 2013. 169 funds tracked by Wall St. Rank hold SPPI as of Q4 2019.

Bessemer Group reported no remaining Spectrum Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
Bessemer Group sold 87 Spectrum Pharmaceuticals Inc shares in Q4 2019, an estimated $1K.
Bessemer Group first reported a position in Spectrum Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
Bessemer Group's Spectrum Pharmaceuticals Inc position peaked at $841K in Q2 2013.
169 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q4 2019.

Based on Bessemer Group's 13F filing for Q4 2019, filed 4 Feb 2020.